Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies

3721 - Randomized phase II trial of CODE or AP after chemoradiotherapy for LD-SCLC: long-term survival and toxicity analysis


29 Sep 2019


Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies


Ikuo Sekine


Annals of Oncology (2019) 30 (suppl_5): v710-v717. 10.1093/annonc/mdz264


I. Sekine1, H. Harada2, N. Yamamoto3, M. Wakabayashi4, H. Murakami5, K. Goto6, N. Nogami7, T. Seto8, F. Oshita9, H. Okamoto10, H. Tanaka11, T. Tamura12, S. Ishikura13, Y. Ohe3

Author affiliations

  • 1 Department Of Medical Oncology, Faculty of Medicine, University of Tsukuba, 305-8575 - Tsukuba/JP
  • 2 Division Of Radiation Therapy, Shizuoka Cancer Center, Nagaizumi/JP
  • 3 Department Of Thoracic Oncology, National Cancer Center Hospital, Tokyo/JP
  • 4 Jcog Data Center, National Cancer Center Hospital, Tokyo/JP
  • 5 Division Of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi/JP
  • 6 Department Of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa/JP
  • 7 Department Of Respiratory Medicine, National Hospital Organization Shikoku Cancer Center, Matsuyama/JP
  • 8 Department Of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka/JP
  • 9 Department Of Thoracic Oncology, Kanagawa Cancer Center, Yokohama/JP
  • 10 Department Of Respiratory Medicine, Yokohama Municipal Citizen's Hospital, Yokohama/JP
  • 11 Department Of Internal Medicine, Niigata Cancer Center Hospital, Niigata/JP
  • 12 Thoracic Center, St. Luke's International Hospital, Tokyo/JP
  • 13 Department Of Radiology, Nagoya City University Graduate School of Medical Sciences, Nagoya/JP


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 3721


The objective of this study was to select, for a phase III trial, the more promising of weekly-dose intensive chemotherapy or amrubicin plus cisplatin as subsequent therapy after induction chemoradiotherapy for previously untreated limited-disease small cell lung cancer (LD-SCLC).


Patients (pts) aged 20-70 years with untreated clinical stage II/III LD-SCLC were eligible. After one cycle of accelerated hyperfractionation thoracic radiotherapy with etoposide plus cisplatin, pts without progression were randomized to either 3 cycles of cisplatin 25 mg/m2 (days 1, 8), doxorubicin 40 mg/m2 (day 1), etoposide 80 mg/m2 (days 1-3), and vincristine 1 mg/m2 (day 8) every 2 weeks (CODE) or amrubicin 40 mg/m2 (days 1-3) and cisplatin 60 mg/m2 (day 1) every 3 weeks (AP). The primary endpoint was the 1-year progression-free survival (PFS) after randomization. The sample size was 72 to select the arm yielding a better 1-year PFS (55% vs. 65%) with a correct selection probability of 80%.


From March 2011 to February 2014, 85 pts were registered. After the induction chemoradiotherapy, 75 pts were randomized to CODE (n = 39) or AP (n = 36). The one-year PFS (95% CI) was 41.0% (25.7-55.8) in the CODE arm and 54.3% (36.6-69.0) in the AP arm. Grade 4 neutropenia and grade 3 febrile neutropenia occurred in 47% and 16% in the CODE arm and 78% and 42% in the AP arm, respectively. In patients aged 61 years or older, they were noted in 48% and 19% in the CODE arm and 88% and 48% in the AP arm, respectively. In women, they were noted in 20% and none in the CODE arm and 86% and 71% in the AP arm, respectively. Grade 3 pneumonitis was noted in one patient each in both arms. Secondary malignancies developed in 4 pts in the CODE arm and 2 pts in the AP arm. The 5-year survival (95% CI) in all 85 pts was 43.2% (32.5-53.4). The 5-year survival in all pts after randomization for CODE and AP arms were 35.3% (20.6-50.2) and 45.2% (28.3-60.7), respectively. The HR (95% CI) of AP arms to CODE arm was 0.70 (0.39-1.25).


An overall survival profile of AP was relatively good when compared to that of the historical control, but hematological toxicity was severe in AP, especially in older and female patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.